Only days after the Food and Drug Administration cleared Diatide's acute venous thrombosis imaging agent AcuTect (SCAN 9/30/98), the Londonderry, NH, radiopharmaceutical firm received a $2 million milestone payment from marketing partner Nycomed Amersham
Only days after the Food and Drug Administration cleared Diatide's acute venous thrombosis imaging agent AcuTect (SCAN 9/30/98), the Londonderry, NH, radiopharmaceutical firm received a $2 million milestone payment from marketing partner Nycomed Amersham of Buckinghamshire, U.K. The cash is the second payment Diatide has received from Nycomed Amersham in the last two months: In August, Diatide received $2 million for filing a new drug application for NeoTect, its lung cancer imaging agent.
Could Virtual Non-Contrast Images from Photon-Counting CT Reduce Radiation Dosing with CCTA?
March 28th 2024Emerging research on coronary artery calcium scoring for the assessment of coronary artery disease (CAD) suggests the use of virtual non-contrast images from photon-counting CT may lead to a nearly 20 percent reduction in radiation dosing.
FDA Clears CT-Based AI Tools for PE Detection and Stroke Severity Assessment
March 26th 2024The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.